



The Indonesian Journal of General Medicine

A Comprehensive Literature Review of Effect of Mineralocorticoid Receptor Blockers on Chronic Kidney Disease

¹ Erick Persson Jeffry, ² Charles Sanjaya Seikka

¹ Faculty of Medicine, Veterans National Development University, Special
Region of Jakarta, Indonesia

² Internal Medicine Consultant, Kebonjati General Hospital, Bandung City,
Indonesia

Correspondence : erick.persson86@gmail.com

Article History :

Received date : 2024/10/12
Revised date : 2024/11/14
Accepted date : 2024/12/26
Published date : 2025/01/08



Copyright: © 2024 by the
authors. Submitted for possible
open access publication under
the terms and conditions of the
Creative Commons Attribution
(BY NC) license
(<https://creativecommons.org/licenses/by-nc/4.0/>).



ABSTRACT

Background: The literature surrounding the effects of mineralocorticoid receptor blockers on chronic kidney disease (CKD) has evolved significantly over recent years, reflecting a growing understanding of their potential benefits and risks. **Literature Review:** (Yanai et al., 2021) reinforced the cardiovascular protective effects of MRAs through their systematic review and meta-analysis, indicating that MRAs could significantly reduce cardiovascular events in CKD patients. In a similar vein, (B. Wish & Pergola, 2022) discussed the advantages of combining MRAs with ACE inhibitors or ARBs, while cautioning against the elevated risk of hyperkalemia. (Hu et al., 2023) provided a meta-analysis focusing on eplerenone, a selective MRA, suggesting its role as an adjunct therapy in CKD management, although they noted the need for further exploration of its safety profile. (Hedlund Møller et al., 2024) examined the paradoxical nature of MRA treatment, where increased hyperkalemia incidence was associated with decreased mortality risk, underscoring the need for a balanced approach in clinical decision-making. This duality illustrates the necessity of vigilant monitoring and patient management strategies to optimize the therapeutic benefits of MRAs while minimizing risks. **Conclusion:** In conclusion, the collective findings from these studies indicate that MRAs hold significant promise in the management of CKD, particularly in reducing proteinuria and offering cardiovascular protection. However, the associated risk of hyperkalemia poses a critical barrier to their widespread use. Future research is essential to further elucidate the long-term outcomes of MRA therapy, explore novel agents that separate organ protection from adverse effects, and establish guidelines that can enhance patient safety while maximizing therapeutic benefits.

Keyword: Effect, Mineralocorticoid Receptor Blockers, Chronic Kidney Disease

INTRODUCTION

The literature surrounding the effects of mineralocorticoid receptor blockers on chronic kidney disease (CKD) has evolved significantly over recent years, reflecting a growing understanding of their potential benefits and risks. In 2016, (Currie et al., 2016) conducted a systematic review and meta-analysis that highlighted the utility of mineralocorticoid receptor antagonists (MRAs) in managing proteinuria and delaying CKD progression, particularly in patients already receiving renin-angiotensin system inhibitors. They noted that while MRAs could effectively reduce blood pressure and proteinuria, the associated risk of hyperkalemia posed a significant barrier to their widespread use in CKD patients. Building on this foundation, (Bamberg et al., 2018) explored the preclinical pharmacology of a novel MRA, AZD9977, which aims to separate organ protection from electrolyte excretion effects. Their findings suggested that while traditional MRAs like spironolactone and eplerenone provide benefits in reducing proteinuria and slowing

CKD progression, the risk of hyperkalemia remains a critical limitation. The study posited that selective MRAs could offer significant therapeutic advantages by mitigating these risks while still providing kidney protection. In 2019, (Blankenburg et al., 2019) examined real-world data on the initiation of MRAs in CKD patients, revealing that the prevalence of CKD often coincided with other chronic conditions such as obesity and diabetes. This study underscored the complexities of managing CKD, particularly in the context of comorbidities, and highlighted the need for careful monitoring of patient characteristics to optimize MRA use.

The exploration of MRAs in diabetic kidney disease (DKD) continued with the work of (Vodošek Hojs et al., 2021), who emphasized the role of MRAs in lowering albuminuria. They noted, however, that hard outcomes related to kidney disease progression and cardiovascular events were still lacking for most MRAs, except for finerenone. The authors suggested that with appropriate management strategies, the use of MRAs could be

expanded, especially with the emergence of non-steroidal alternatives that present lower risks for hyperkalemia. (Yanai et al., 2021) further contributed to the discourse with their systematic review and meta-analysis on the impacts of renin-angiotensin-aldosterone system blockers, including MRAs, on cardiovascular disease in CKD patients. Their results reinforced the cardiovascular protective effects of MRAs, particularly in pre-dialysis and on-dialysis patients, thereby highlighting their multifaceted role in CKD management. (B. Wish & Pergola, 2022) reflected on the evolution of MRAs in treating CKD associated with type 2 diabetes mellitus, reiterating the benefits of combining MRAs with ACE inhibitors or ARBs for organ protection while cautioning against the heightened risk of hyperkalemia.

Their review indicated that while MRAs can improve proteinuria and blood pressure, the risks associated with their use necessitate careful consideration in clinical practice. Most recently, (Hu et al., 2023) conducted a meta-analysis evaluating the efficacy and safety of

eplerenone, a selective MRA, for CKD treatment. Their findings suggested that eplerenone could be a valuable adjunct therapy for CKD, emphasizing the need for comprehensive analyses of its clinical application and safety profiles. Finally, (Hedlund Møller et al., 2024) investigated the implications of MRA treatment in renal insufficiency, specifically focusing on hyperkalemia and mortality risks. Their study found that while MRA treatment was linked to an increased incidence of hyperkalemia, it was also associated with a decreased risk of subsequent mortality, illustrating the complex balance between therapeutic benefits and potential adverse effects. These articles collectively underscore the nuanced landscape of MRA use in CKD, highlighting both their therapeutic potential and the critical risks that must be managed to optimize patient outcomes.

LITERATURE REVIEW

The article titled "Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis" by Currie et al. (Currie

et al., 2016) provides a comprehensive evaluation of the role of mineralocorticoid receptor antagonists (MRAs) in the management of chronic kidney disease (CKD), particularly focusing on their effects on proteinuria and disease progression. The authors highlight the significance of targeting the renin-angiotensin system (RAS) in CKD, especially in patients with concomitant proteinuria and hypertension, as this approach has been traditionally effective in mitigating disease advancement.

The systematic review and meta-analysis conducted by Currie et al. is notable for its rigorous methodology, incorporating both selective and non-selective MRAs across various stages of CKD. This inclusivity allows for a more nuanced understanding of the efficacy of MRAs in renal protection. The authors critically assess previous findings, including a landmark 2009 meta-analysis that established the beneficial effects of adding MRAs to RAS blockade, which resulted in reductions in blood pressure and proteinuria. However, they also acknowledge the significant risk of

hyperkalemia, a common side effect that poses a challenge for the clinical application of MRAs in CKD patients.

One of the key contributions of this article is the updated meta-analysis that utilizes unpublished data, which enhances the robustness of their findings. The authors meticulously evaluate the balance between the renoprotective benefits of MRAs and the potential adverse effects, particularly hyperkalemia. This analysis is crucial as it addresses a pressing clinical concern: whether the advantages of employing MRAs in CKD management justify the risks associated with their use.

The article's findings suggest that while MRAs can significantly reduce proteinuria and slow CKD progression, careful patient selection and monitoring for hyperkalemia are essential. The authors emphasize the need for further research to delineate the long-term outcomes of MRA therapy in CKD and to establish guidelines that can optimize patient safety while maximizing therapeutic benefits.

The article titled "Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion" by Bamberg et al. (Bamberg et al., 2018) provides a comprehensive exploration of the role of mineralocorticoid receptors (MR) in chronic kidney disease (CKD) and presents a novel approach to MR modulation. The authors elucidate the multifaceted nature of MR activation, emphasizing its critical involvement in renal physiology and pathology, particularly in the context of CKD.

The main idea of the article revolves around the dual role of MR: while it is essential for maintaining electrolyte and fluid balance through aldosterone signaling in kidney tubules, its pathological activation in non-epithelial cells contributes significantly to organ dysfunction. This pathological activation is implicated in promoting inflammation, oxidative stress, and fibrosis, which are known to exacerbate CKD and increase the risk of cardiovascular events (Bamberg et al., 2018). The authors effectively argue that MR activation serves as an

independent mediator of renal vascular disease, highlighting the need for targeted therapeutic strategies that can mitigate these adverse effects without compromising electrolyte homeostasis.

A critical evaluation of the article reveals a well-structured argument supported by a robust synthesis of existing literature on MR antagonists, such as spironolactone and eplerenone. The authors note the limitations of these traditional MR antagonists, particularly their propensity to cause hyperkalemia, which poses significant risks to patients with impaired renal function. This limitation underscores the need for a selective MR modulator like AZD9977, which aims to provide organ protection by antagonizing MR in non-epithelial cells while preserving electrolyte handling in epithelial cells (Bamberg et al., 2018). The potential of AZD9977 to separate these effects is a significant advancement in the field, as it could lead to improved therapeutic outcomes for CKD patients.

Moreover, the authors present evidence from clinical studies indicating that MR antagonists can improve proteinuria and potentially slow CKD progression, suggesting that the kidney protective effects of MRAs extend beyond mere blood pressure reduction (Bamberg et al., 2018). This insight is crucial as it shifts the focus toward understanding the underlying mechanisms of MR activation in CKD and the multifactorial benefits of MR blockade.

The article "Patient characteristics and initiation of mineralocorticoid receptor antagonists in patients with chronic kidney disease in routine clinical practice in the US: a retrospective cohort study" by Blankenburg et al. (Blankenburg et al., 2019) provides a comprehensive examination of the initiation and effects of mineralocorticoid receptor antagonists (MRAs) among patients with chronic kidney disease (CKD) in a clinical setting. The authors highlight the multifaceted relationship between CKD and various comorbid conditions, including obesity, diabetes,

hypertension, and heart failure, underscoring the complexity of managing these patients.

One of the key insights from the article is the role of overactivated mineralocorticoid receptors in exacerbating cardiovascular disease and CKD. The authors discuss how MRAs, specifically spironolactone and eplerenone, have been shown to confer benefits such as reduced blood pressure, decreased cardiovascular mortality, and improved albuminuria excretion in CKD patients (Blankenburg et al., 2019). This aligns with existing literature that supports the therapeutic use of MRAs in managing heart failure and CKD, particularly in patients with type 2 diabetes mellitus, which is a significant contributor to end-stage renal disease (ESRD).

However, the article also critically evaluates the limitations associated with the use of MRAs. The authors acknowledge the adverse reactions linked to these medications, such as hyperkalemia and potential worsening of renal function, which can complicate their use in CKD patients who often present with

multiple comorbidities. This cautionary perspective is essential for clinicians to consider when prescribing MRAs, as the balance between the potential benefits and risks must be carefully managed.

Furthermore, the study's retrospective cohort design allows for an examination of real-world data, providing valuable insights into patient characteristics and treatment patterns. However, the authors note that previous research has not sufficiently explored the association between MRAs and therapeutic outcomes in CKD patients with varying comorbid conditions. This gap in the literature suggests a need for further investigation to better understand the efficacy and safety of MRAs in this population.

The article "Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease" by Vodošek Hojs et al. (Vodošek Hojs et al., 2021) provides a comprehensive overview of the role of mineralocorticoid receptor antagonists (MRAs) in the context of diabetic kidney disease (DKD). The authors highlight the significant potential of MRAs in

reducing albuminuria, which is a crucial marker for kidney damage and progression of chronic kidney disease. This reduction in albuminuria is particularly relevant for patients with DKD, as it may indicate a slowing of disease progression.

One of the notable points made in the article is the lack of robust data on hard outcomes, such as kidney disease progression, cardiovascular events, and mortality associated with MRAs, aside from the emerging data on finerenone. This gap in research underscores a critical limitation in the current understanding of MRAs' long-term benefits and risks in DKD management. The authors rightly emphasize that while the immediate benefits of lowering albuminuria are promising, the absence of data on hard outcomes necessitates cautious interpretation of these results and the need for further studies.

The article also addresses the challenges associated with the use of steroidal MRAs, particularly the risk of hyperkalemia, which can limit their clinical application. This is an important consideration for healthcare providers, as hyperkalemia

can lead to serious complications if not managed appropriately. The introduction of non-steroidal MRAs, which are associated with a lower incidence of hyperkalemia, presents a potential advancement in the treatment landscape for DKD. The authors suggest that these non-steroidal MRAs could become more commonplace in clinical practice, which could enhance patient safety and broaden treatment options.

The article titled "Systematic Review and Meta-Analysis of Renin–Angiotensin–Aldosterone System Blocker Effects on the Development of Cardiovascular Disease in Patients With Chronic Kidney Disease" by Katsunori Yanai, Kenichi Ishibashi, and Yoshiyuki Morishita (Yanai et al., 2021) provides a comprehensive analysis of the effects of mineralocorticoid receptor antagonists (MRAs) on cardiovascular outcomes in patients with chronic kidney disease (CKD).

The authors present a systematic review and meta-analysis that synthesizes data from multiple studies, focusing on the role of MRAs, particularly spironolactone, in

reducing cardiovascular events among CKD patients. A significant finding highlighted in the article is that the administration of spironolactone over a duration of six years resulted in a marked decrease in cardiovascular incidents in pre-dialysis patients suffering from chronic heart failure. This finding is crucial as it underscores the potential of MRAs not only to manage hypertension but also to provide protective cardiovascular benefits in a vulnerable patient population.

The meta-analysis conducted by Yanai et al. effectively aggregates evidence demonstrating that MRAs confer protective effects against cardiovascular disease in both pre-dialysis and on-dialysis patients with CKD. The authors meticulously detail the methodology employed in their review, including the criteria for study selection and the statistical analyses used to evaluate the pooled data. This rigorous approach enhances the credibility of their conclusions and provides a solid foundation for the implications of MRA therapy in clinical practice.

However, while the findings are compelling, the article could benefit from a more in-depth discussion on the underlying mechanisms through which MRAs exert their cardiovascular protective effects. Understanding the pathophysiological pathways involved could provide further insights into optimizing treatment strategies for CKD patients. Additionally, the article could address potential limitations of the included studies, such as variability in patient populations and treatment protocols, which may influence the generalizability of the results.

The article titled "Evolution of Mineralocorticoid Receptor Antagonists in the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus" by Wish and Pergola (B. Wish & Pergola, 2022) provides a comprehensive overview of the role of mineralocorticoid receptor antagonists (MRAs) in managing chronic kidney disease (CKD) among patients with type 2 diabetes mellitus. The authors synthesize findings from various systematic reviews and meta-analyses, highlighting both the

therapeutic benefits and the associated risks of MRAs.

The article underscores that the addition of steroidal MRAs to a treatment regimen that includes angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB) can enhance organ protection for CKD patients, particularly in terms of reducing proteinuria and systolic blood pressure (B. Wish & Pergola, 2022). However, this benefit comes with a significant caveat: an increased risk of hyperkalemia, acute kidney injury, and other adverse effects, such as gynecomastia. The authors reference a Cochrane systematic review that corroborates earlier findings regarding the balance of benefits and risks associated with MRA therapy, emphasizing the necessity for cautious patient selection and monitoring.

A critical evaluation of the evidence presented reveals that while MRAs appear to be beneficial in managing certain aspects of CKD, the overall impact on disease progression, cardiovascular outcomes, and mortality remains inconclusive. The

article notes that although MRAs can reduce blood pressure and albuminuria, the higher incidence of hyperkalemia leading to patient withdrawal from studies raises concerns about their safety profile when used in conjunction with ACEi or ARB (B. Wish & Pergola, 2022). This finding is particularly relevant given the vulnerability of CKD patients to electrolyte imbalances.

Moreover, the authors point out several limitations within the existing studies, including the short duration of treatment, lack of patient-centered outcomes, and the infrequent inclusion of patients with severe CKD. These limitations suggest that the current body of literature may not fully capture the long-term effects and safety of MRAs in diverse patient populations. The inconsistency in study methodologies and outcomes reporting further complicates the interpretation of the data, indicating a need for more rigorously designed trials to establish clearer guidelines for the use of MRAs in CKD management.

The article titled "Efficacy and Safety of Eplerenone for Treating

Chronic Kidney Disease: A Meta-Analysis" by Hu et al. (Hu et al., 2023) provides a comprehensive examination of the role of eplerenone, a second-generation selective mineralocorticoid receptor antagonist (MRA), in the management of chronic kidney disease (CKD). The authors highlight CKD as a significant public health issue, emphasizing its contribution to the global burden of disease. They argue that traditional treatments, such as angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARBs), while effective in reducing proteinuria and protecting kidney function, may not fully address the complexities of CKD management.

The meta-analysis conducted by Hu et al. systematically evaluates the safety and efficacy of eplerenone, particularly its role in mitigating the effects of excessive mineralocorticoid receptor (MR) activation. The authors present evidence suggesting that eplerenone can serve as a valuable adjunct therapy in CKD treatment, potentially enhancing renal protection beyond what is achievable with ACEIs and ARBs alone. This is

particularly relevant given the pathophysiological role of the renin-angiotensin-aldosterone system (RAAS) in CKD progression.

One of the strengths of the article is its rigorous methodology, which includes a thorough review of clinical indicators closely linked to CKD prognosis. The authors provide a detailed analysis of various clinical outcomes, such as changes in serum creatinine levels, proteinuria, and overall kidney function. This quantitative assessment lends credibility to their conclusions regarding the efficacy of eplerenone.

However, the article does have limitations that warrant consideration. While the authors effectively summarize the positive aspects of eplerenone therapy, there is relatively less emphasis on the potential adverse effects associated with MRA use. The safety profile of eplerenone, particularly in populations with varying comorbidities, could benefit from further exploration. Additionally, the heterogeneity of the studies included in the meta-analysis may pose challenges in generalizing the

findings across different patient populations.

The article titled "Mineralocorticoid receptor antagonist treatment in patients with renal insufficiency and the associated risk of hyperkalemia and death" by Møller et al. (Hedlund Møller et al., 2024) provides a comprehensive examination of the implications of mineralocorticoid receptor antagonists (MRAs) in the context of chronic kidney disease (CKD). The authors effectively highlight the dual nature of MRA treatment: while it offers kidney protection, it simultaneously poses significant risks, particularly in patients with advanced renal failure.

The study's primary focus is on the balance between the therapeutic benefits of MRAs and the associated risks of hyperkalemia and mortality. The findings indicate that while MRA treatment leads to an increased incidence of hyperkalemia, it is also correlated with a reduced risk of 30-day mortality across all stages of renal impairment. This paradox presents a critical dilemma for clinicians, as the management of

CKD often requires a careful consideration of the risks versus benefits of various treatments, especially in patients who are already vulnerable due to renal insufficiency.

Møller et al. (Hedlund Møller et al., 2024) contextualize their findings within the broader landscape of CKD management, where the primary therapeutic strategies have traditionally centered around angiotensin-converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARBs). The authors argue that MRAs provide an additional layer of protection by further inhibiting the renin-angiotensin-aldosterone system (RAAS), which is crucial given the high prevalence of heart failure in CKD patients—a condition that significantly contributes to mortality.

The article's critical evaluation of the current therapeutic landscape is particularly noteworthy. By emphasizing the importance of evidence-based implementation of MRAs alongside established treatments, the authors advocate for a more nuanced approach to managing CKD. They encourage clinicians to

weigh the potential benefits of MRAs against the risk of hyperkalemia, especially in advanced stages of renal disease.

Moreover, the discussion surrounding the implications of hyperkalemia is crucial, as it underscores the need for vigilant monitoring and management strategies in patients receiving MRA therapy. The authors do well to remind the reader that while the short-term benefits of reducing mortality risk are significant, the long-term management of hyperkalemia remains a pressing concern that cannot be overlooked.

CONCLUSION

The literature on mineralocorticoid receptor blockers (MRAs) in chronic kidney disease (CKD) highlights their potential benefits in managing the disease while also emphasizing the associated risks, particularly hyperkalemia. (Currie et al., 2016) conducted a systematic review and meta-analysis that established MRAs' efficacy in reducing proteinuria and delaying CKD progression, especially in patients already treated with renin-

angiotensin system (RAS) inhibitors. They acknowledged the challenge posed by hyperkalemia, which remains a significant concern in clinical practice. (Bamberg et al., 2018) introduced AZD9977, a novel MRA designed to mitigate hyperkalemia risks while providing renal protection, showcasing an evolution in MRA pharmacology that could enhance patient safety.

Further investigations, such as those by (Blankenburg et al., 2019), explored the initiation of MRAs in CKD patients, revealing the complexity of managing CKD alongside comorbidities like obesity and diabetes. This complexity necessitates careful patient selection and monitoring to optimize therapeutic outcomes. (Vodošek Hojs et al., 2021) specifically addressed MRAs' role in diabetic kidney disease (DKD), noting the promise of reducing albuminuria but also highlighting the lack of robust data on long-term outcomes related to kidney disease progression and cardiovascular events.

(Yanai et al., 2021) reinforced the cardiovascular protective effects

of MRAs through their systematic review and meta-analysis, indicating that MRAs could significantly reduce cardiovascular events in CKD patients. In a similar vein, (B. Wish & Pergola, 2022) discussed the advantages of combining MRAs with ACE inhibitors or ARBs, while cautioning against the elevated risk of hyperkalemia. (Hu et al., 2023) provided a meta-analysis focusing on eplerenone, a selective MRA, suggesting its role as an adjunct therapy in CKD management, although they noted the need for further exploration of its safety profile.

(Hedlund Møller et al., 2024) examined the paradoxical nature of MRA treatment, where increased hyperkalemia incidence was associated with decreased mortality risk, underscoring the need for a balanced approach in clinical decision-making. This duality illustrates the necessity of vigilant monitoring and patient management strategies to optimize the therapeutic benefits of MRAs while minimizing risks.

In conclusion, the collective findings from these studies indicate that MRAs hold significant promise in the management of CKD, particularly in reducing proteinuria and offering cardiovascular protection. However, the associated risk of hyperkalemia poses a critical barrier to their widespread use. Future research is essential to further elucidate the long-term outcomes of MRA therapy, explore novel agents that separate organ protection from adverse effects, and establish guidelines that can enhance patient safety while maximizing therapeutic benefits.

DISCLOSURE STATEMENT

- Disclosure Statement : The authors have no conflicts of Interest to declare
- Funding Sources : None
- Acknowledgements : -
- Author Contribution : All authors discussed and contributed the final content for journal submission and publication

REFERENCES

1. Currie, G., H. M. Taylor, A., Fujita, T., Ohtsu, H.,

- Lindhardt, M., Rossing, P., Boesby, L., C. Edwards, N., J. Ferro, C., N. Townend, J., H. van den Meiracker, A., G. Saklayen, M., Oveisi, S., G. Jardine, A., Delles, C., J. Preiss, D., & B. Mark, P., 2016. Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis. ncbi.nlm.nih.gov
2. Bamberg, K., Johansson, U., Edman, K., William-Olsson, L., Myhre, S., Gunnarsson, A., Geschwindner, S., Aagaard, A., Björnson Granqvist, A., Jaisser, F., Huang, Y., L. Granberg, K., Jansson-Löfmark, R., & Hartleib-Geschwindner, J., 2018. Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion. ncbi.nlm.nih.gov
3. Blankenburg, M., Fett, A. K., Eisenring, S., Haas, G., &

- Gay, A., 2019. Patient characteristics and initiation of mineralocorticoid receptor antagonists in patients with chronic kidney disease in routine clinical practice in the US: a retrospective cohort study. ncbi.nlm.nih.gov
4. Vodošek Hojs, N., Bevc, S., Ekart, R., Piko, N., Petreski, T., & Hojs, R., 2021. Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease. ncbi.nlm.nih.gov
5. Yanai, K., Ishibashi, K., & Morishita, Y., 2021. Systematic Review and Meta-Analysis of Renin–Angiotensin–Aldosterone System Blocker Effects on the Development of Cardiovascular Disease in Patients With Chronic Kidney Disease. ncbi.nlm.nih.gov
6. B. Wish, J. & Pergola, P., 2022. Evolution of Mineralocorticoid Receptor Antagonists in the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus. ncbi.nlm.nih.gov
7. Hu, H., Cao, M., Sun, Y., Jin, X., Zhao, X., & Cong, X., 2023. Efficacy and Safety of Eplerenone for Treating Chronic Kidney Disease: A Meta-Analysis. ncbi.nlm.nih.gov
8. Hedlund Møller, S., Haagensen Kofod, D., Schou, M., Torp-Pedersen, C., Gislason, G., Carlson, N., & Lindhardt, M., 2024. Mineralocorticoid receptor antagonist treatment in patients with renal insufficiency and the associated risk of hyperkalemia and death. ncbi.nlm.nih.gov